COVID-19
We need your help. Join us in the fight against the global pandemic.
Addressing COVID-19.
Repurpose.ai has joined the fight to battle the global COVID-19 pandemic. We are harnessing the predictive prowess of our AI Drug Discovery Platform to discover drugs that may be repurposed and serve as therapeutics to prevent individuals from being infected and/or treat individuals infected with the novel coronavirus.
Repurpose.ai has already identified molecules predicted to bind Angiotensin-Converting Enzyme 2 (ACE2), which may block SARS-CoV-2 spike protein-mediated cell fusion.
We have re-engineered our AI Drug Discovery platform to focus exclusively on ACE2 and other biological targets known to play a role in infection, infection progression and symptoms of infection. Our probabilistic model has shown to be far more effective than existing attempts using deterministic approaches. We have already discovered several leads and are identifying laboratories and partners capable of conducting ACE2 binding assays to experimentally confirm these hits.
The drugs that Repurpose.ai discovers for COVID-19 can enter clinical trials essentially immediately. Repurpose.ai’s drug library is comprised of drugs previously approved by the FDA, and similar, or drugs that have successfully navigated a Phase I clinical trial, at minimum. All drugs have a full pre-clinical program, an existing or legacy supply chain and are known to be safe and well tolerated in humans.
Here’s how you can help us discover a treatment.
If you are a member of the following organizations or know someone who is, please contact us to discover how we can collaborate to stop this pandemic.
GOVERNMENT (Examples: Department of Health and Human Services (BARDA, NIH), DoD, NSF, DHS, Congress)
FOUNDATIONS (Examples: Gates Foundation and similar)
COMMERCIAL (Example: Strategic Pharma Companies)
Leveraging our technology to stop COVID-19.
We have developed an AI enabled Digital Chemistry Platform that identifies opportunities to repurpose approved drugs or drugs that have successfully completed Phase I clinical trials.
Our platform leverages:
A Proprietary Database that leverages the historical compendium of drug development data.
Unbiased AI/ML that creates unbiased predictions, minimizing false positives and false negatives.
Algorithms that do not require new experimental data that is not already in the literature.
Discoveries that can be experimentally validated radidly via assays that typically take less than 1 day to complete.
Drugs that can initiate clinical trials rapidly because they have a full pre-clinical program, an existing or legacy supply chain and are known to be safe and well tolerated in humans.
Discovering Therapeutics for COVID-19
Repurpose.ai’s unique approach is capable of discovering attributes relevant to binding potency, intrinsic to the chemical composition of molecules, that are not readily discernible using empirical methods.